Glaucoma News and Research

Latest Glaucoma News and Research

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser.

23 Apr 2014

Glaucoma drug may help reverse obesity-related vision loss in women

An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health.

23 Apr 2014

New edition of RADAR includes review of glycopyrronium for COPD treatment

NPS MedicineWise has published a new edition of RADAR, including a review of glycopyrronium (Seebri Breezhaler), a new medicine for the treatment of chronic obstructive pulmonary disease (COPD).

10 Apr 2014

Leica Microsystems and TrueVision 3D Surgical expand relationship into the ophthalmology arena

TrueVision 3D Surgical, a world leader in neuro and ophthalmic 3D surgical visualization, and Leica Microsystems, a world leader in microscopes and scientific instruments, announced an expansion of their existing partnership into the ophthalmology arena.

From Leica Microsystems GmbH 2 Apr 2014

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma.

31 Mar 2014

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).

27 Mar 2014

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.

18 Mar 2014

Perrigo launches methazolamide tablets

Perrigo Company today announced that it has launched, through a distribution and supply agreement, methazolamide tablets, the generic equivalent to Neptazane tablets. This product is a component of the contingent rights Perrigo received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals, LLC and its affiliates in June of last year.

12 Mar 2014

Research explores new diagnostic strategies to detect glaucoma

Research exploring several new diagnostic strategies to find the earliest changes in the eye to detect glaucoma is underway at the University of Alabama at Birmingham School of Optometry. One optometrist says awareness of this eye disorder is just as important as continuing to study it.

7 Mar 2014

ACADIA Pharmaceuticals proposes to sell common stock in underwritten public offering

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

New corneal layer important for intraocular pressure maintenance

UK researchers have found that a newly discovered layer of the human eye is an important part of the structural tissue that helps to maintain intraocular pressure and thus may play a role in the development of glaucoma.

27 Feb 2014

UAB launches pilot program to detect earlier stages of glaucoma

Glaucoma is a silent disease. It does not hurt, symptoms are slow to develop, and most people do not notice any loss of vision until it is too late. A project by ophthalmologists at the University of Alabama at Birmingham will examine whether a partnership with community-based optometrists will improve detection and treatment of glaucoma, especially for high-risk populations.

27 Feb 2014

Jackson Laboratory Assistant Professor wins 2013 Lewis Rudin Glaucoma Prize from NYAM

Jackson Laboratory Assistant Professor Gareth Howell, Ph.D., is one of two winners of the 2013 Lewis Rudin Glaucoma Prize from The New York Academy of Medicine.

24 Feb 2014

IIN collaborates with Nanyang Technological University to establish Nanomedicine

Northwestern University's International Institute for Nanotechnology (IIN) is collaborating with Nanyang Technological University (NTU), Singapore, to establish the NTU-Northwestern Institute for Nanomedicine.

24 Feb 2014

Study reveals that color vision abnormalities increase with age

Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry.

24 Feb 2014

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

By 2020, nearly 80 million people are expected to have glaucoma, a disorder of the eye that, if left untreated, can damage the optic nerve and eventually lead to blindness.

19 Feb 2014

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, performed the first procedures using the ReSure Sealant on his cataract patients in Durham, North Carolina. The ReSure Sealant is the first FDA-approved sealant for ophthalmic use to seal incisions following cataract surgery.

18 Feb 2014

Dua's Layer in the human cornea may be linked to glaucoma

A new layer in the human cornea - discovered by researchers at The University of Nottingham last year - plays a vital role in the structure of the tissue that controls the flow of fluid from the eye, research has shown.

17 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Glaucoma News and Research

Latest Glaucoma News and Research

NovaBay introduces new eye care product to help patients with eyelids irritation

Glaucoma drug may help reverse obesity-related vision loss in women

New edition of RADAR includes review of glycopyrronium for COPD treatment

Leica Microsystems and TrueVision 3D Surgical expand relationship into the ophthalmology arena

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

pSivida resubmits New Drug Application for ILUVIEN

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Perrigo launches methazolamide tablets

Research explores new diagnostic strategies to detect glaucoma

ACADIA Pharmaceuticals proposes to sell common stock in underwritten public offering

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

New corneal layer important for intraocular pressure maintenance

UAB launches pilot program to detect earlier stages of glaucoma

Jackson Laboratory Assistant Professor wins 2013 Lewis Rudin Glaucoma Prize from NYAM

IIN collaborates with Nanyang Technological University to establish Nanomedicine

Study reveals that color vision abnormalities increase with age

Nanodiamond-drug embedded in contact lenses shows great promise for glaucoma treatment

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Dua's Layer in the human cornea may be linked to glaucoma

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in